Teva Announces Additions to Oncology Biologic Portfolio - Teva Pharmaceutical Indus (NYSE:TEVA)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Teva Pharmaceutical Industries (NYSE: TEVA) today announced two significant additions to its global oncology biologic portfolio with the recent launches of LONQUEX® (lipegfilgrastim) and GRANIX™ (tbo-filgrastim) Injection, and an update on the review status of balugrastim by the U.S. Food and Drug Administration (FDA). Teva launched LONQUEX® (long-acting G-CSF) in Germany on November 4, 2013 – the first launch as part of an EU-wide approval. Teva plans to continue the roll-out of Lonquex across additional countries covered by the European Marketing Approval over the coming months. Also this month, Teva launched GRANIX™ (short-acting G-CSF) in the U.S. on November 11, 2013, marking the entry of the first new G-CSF to the US market in more

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release